GlassScriptPhysician profile
Lakeisha Kelly
NPI 1194496307
$10,182.08
in general payments reported to CMS, 2019-2025
36 companies · $4,452 in 2025
The $4,452 reported for 2025 was more than what 98% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $415 · 2022: $1,326 · 2023: $1,337 · 2024: $2,652 · 2025: $4,452.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,911 · Consulting Fee: $480 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $50.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,911.41 |
| Consulting Fee | $480.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $50.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,279.95 | 2022-2025 | Airsupra, Farxiga, Wainua |
| Novo Nordisk INC | $930.31 | 2021-2025 | Wegovy |
| Teva Pharmaceuticals USA, INC. | $757.04 | 2023-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Otsuka America Pharmaceutical, INC. | $638.34 | 2023-2025 | Rexulti |
| Amgen INC. | $589.76 | 2024-2025 | Tezspire, Repatha, Evenity |
| Ascensia Diabetes Care US INC. | $480.00 | 2025 | |
| Abbvie INC. | $422.65 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $370.92 | 2022-2025 | Cobenfy, Camzyos |
| Neurocrine Biosciences, INC. | $352.68 | 2023-2025 | Ingrezza |
| Axsome Therapeutics, INC. | $346.70 | 2024-2025 | Auvelity |
| Lundbeck LLC | $312.69 | 2024-2025 | Rexulti |
| Coloplast Corp | $297.13 | 2023-2025 | Titan, Altis |
| Edwards Lifesciences Corporation | $260.59 | 2024-2025 | Edwards Sapien 3 Transcatheter Heart Valve (Thv), Sapien 3 Ultra Resilia |
| Tris Pharma INC | $243.38 | 2025 | Dyanavel Xr, Quillichew Er, Quillivant |
| Averitas Pharma INC. | $235.24 | 2024-2025 | Qutenza |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $226.38 | 2022 | |
| Convatec INC. | $223.27 | 2021-2022 | |
| Organon LLC | $174.08 | 2022 | |
| Inari Medical, INC. | $146.00 | 2022 | |
| Alexion Pharmaceuticals, INC. | $130.11 | 2024 | |
| Madrigal Pharmaceuticals | $125.12 | 2025 | Rezdiffra |
| Tempus Ai, INC | $124.38 | 2024 | |
| Exeltis, USA INC. | $123.98 | 2025 | |
| Qol Medical, LLC | $123.73 | 2024 | Sucraid |
| Collegium Pharmaceutical, INC. | $117.00 | 2025 | Jornay Pm |
| Novartis Pharmaceuticals Corporation | $116.97 | 2024 | |
| Ironwood Pharmaceuticals, INC | $115.32 | 2024 | |
| Melinta Therapeutics, LLC | $114.33 | 2022 | |
| Sanofi-Aventis U.S. LLC | $113.34 | 2021 | |
| Paratek Pharmaceuticals, INC. | $113.06 | 2025 | Nuzyra |
| Antares Pharma, INC. | $112.63 | 2022 | |
| Urovant Sciences INC | $112.30 | 2022 | |
| Genzyme Corporation | $107.42 | 2025 | |
| Kci USA, INC. | $106.35 | 2023 | Activ.A.C. |
| Bayer Healthcare Pharmaceuticals INC. | $88.93 | 2023 | |
| Senseonics, Incorporated | $50.00 | 2024 | Eversense |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lakeisha Kelly listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.